- Trials with a EudraCT protocol (39,306)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
39,306 result(s) found for: 1.
Displaying page 1,354 of 1,966.
| EudraCT Number: 2007-003569-42 | Sponsor Protocol Number: 20060195 | Start Date*: 2007-09-29 | |||||||||||
| Sponsor Name:Amgen Inc. | |||||||||||||
| Full Title: Estudio Aleatorizado, Doble Ciego, Controlado con Placebo, de Fase 1/2 para Determinar la Seguridad y la Eficacia de AMG 531 en Sujetos Pediátricos Trombocitopénicos con Púrpura Trombocitopénica I... | |||||||||||||
| Medical condition: Púrpura Trombocitopénica Inmune (Idiopática) (PTI) | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-000415-32 | Sponsor Protocol Number: DAL-PK-02 | Start Date*: 2022-06-07 | |||||||||||
| Sponsor Name:Allergan | |||||||||||||
| Full Title: Pharmacokinetics of a Single-Dose of Dalbavancin in Preterm Neonates to Infants Ages 3 Months With Suspected or Confirmed Bacterial Infection | |||||||||||||
| Medical condition: Bacterial Infection in hospitalized children | |||||||||||||
|
|||||||||||||
| Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2005-001006-12 | Sponsor Protocol Number: CALIPSO | Start Date*: 2006-04-02 |
| Sponsor Name:Axxonis Pharma GmbH | ||
| Full Title: Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the efficacy and safety of Lisparin®, applied subcutaneously by means of a minipump in patients with advan... | ||
| Medical condition: Patients with advanced Parkinson’s disease with motor fluctuations and “OFF” periods refractory to conventional treatment. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Completed) IT (Completed) CZ (Completed) DE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2019-001835-29 | Sponsor Protocol Number: 201900231 | Start Date*: 2021-01-28 | |||||||||||
| Sponsor Name:University Medical Center Groningen | |||||||||||||
| Full Title: Canagliflozin REnal Distribution Intervention Trial (CREDIT); A feasibility study for the use of 18F-canagliflozin to quantify individual differences in target-site exposure in diabetes patients. | |||||||||||||
| Medical condition: Type 2 diabetes mellitus | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2004-001108-11 | Sponsor Protocol Number: EORTC protocol 62033 | Start Date*: 2004-11-08 | |||||||||||
| Sponsor Name:European Organisation for the Research and Treatment of Cancer | |||||||||||||
| Full Title: A phase II study of intravenous TZT-1027, administered weekly times two, every three weeks, to patients with advanced or metastatic soft tissue sarcomas (STS) with prior exposure to doxorubicin-bas... | |||||||||||||
| Medical condition: Soft Tissue Sarcoma (STS) is a rare group of heterogeneous mesenchymal cancers originating from connective tissue. There are multiple histological subtypes of STS. At present all these subtypes are... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2004-002181-38 | Sponsor Protocol Number: WARCEF | Start Date*: 2004-10-22 |
| Sponsor Name:NIH-National Institut of Health - NINDS-National Institut of Neurogical Disorders and Stroke | ||
| Full Title: Warfarin versus Aspirin in Reduced Ejection Fraction. | ||
| Medical condition: Patients with left ventricular disfunction with ejection fraction less or equal to 35%. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: HU (Completed) SK (Completed) GB (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2012-003147-30 | Sponsor Protocol Number: 1103-CT02 | Start Date*: 2012-11-20 | |||||||||||
| Sponsor Name:Antisense Therapeutics Ltd | |||||||||||||
| Full Title: A Phase II Randomised, Open-Label, Parallel Group Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Two Subcutaneous Dosing Regimens of ATL1103 in Adult Patients with Acromegaly. | |||||||||||||
| Medical condition: Acromegaly | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) ES (Completed) HU (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-009992-36 | Sponsor Protocol Number: S51532 | Start Date*: 2010-11-30 | |||||||||||
| Sponsor Name:University Hospital Leuven | |||||||||||||
| Full Title: A two arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment of K-Ras wild type metastatic colorectal cancer: Everest 2 | |||||||||||||
| Medical condition: K-Ras wild type metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) HU (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-005521-23 | Sponsor Protocol Number: QUAMED13 | Start Date*: 2014-06-19 | ||||||||||||||||
| Sponsor Name:QUALIPHAR NV | ||||||||||||||||||
| Full Title: Efficacy and safety assessment of Chlorhexidine hydrochloride - Lidocaine hydrochloride (MEDICA ®) versus placebo in adult patients with sore throat and/or acute pharyngitis | ||||||||||||||||||
| Medical condition: Sore throat or acute pharyngitis | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DK (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2010-024014-60 | Sponsor Protocol Number: I5A-MC-JAEM | Start Date*: 2011-05-17 | |||||||||||
| Sponsor Name:Eli Lilly and Company Limited, Indianapolis | |||||||||||||
| Full Title: An Open-label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Cisplatin and Pemetrexed With or Without Cixutumumab as First Line Therapy in Patients with Advanced Nonsq... | |||||||||||||
| Medical condition: advanced nonsquamous non-small cell lung carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) IT (Completed) BE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-004425-41 | Sponsor Protocol Number: ESN364-UF-02 | Start Date*: 2015-01-21 | |||||||||||
| Sponsor Name:Euroscreen S.A | |||||||||||||
| Full Title: A Phase IIa, Double-Blind, Placebo-Controlled, Study of ESN364 Administered for 12 Weeks to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Women Presenting With ... | |||||||||||||
| Medical condition: Uterine Fibroids | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: BE (Completed) DE (Completed) AT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-004024-11 | Sponsor Protocol Number: 60-60600-97-103 | Start Date*: 2014-07-23 | |||||||||||
| Sponsor Name:Academic Psychiatric Center - AMC-UvA | |||||||||||||
| Full Title: New pharmacotherapeutic treatment options for crack-cocaine dependent people in the Netherlands: A double-blind, placebo-controlled randomized feasibility study of sustained release dexamphetamine | |||||||||||||
| Medical condition: cocaine dependence (according DSM-IV) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-001504-17 | Sponsor Protocol Number: 16027 | Start Date*: 2022-04-08 | |||||||||||
| Sponsor Name:Bayer AG | |||||||||||||
| Full Title: Prospective, historically controlled study to evaluate the efficacy and safety of a new pediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas’ disease | |||||||||||||
| Medical condition: Chagas disease | |||||||||||||
|
|||||||||||||
| Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-000224-35 | Sponsor Protocol Number: RECEM00001 | Start Date*: 2021-07-28 | |||||||||||
| Sponsor Name:Marie Kristine Jessen | |||||||||||||
| Full Title: Restrictive Fluid Administration vs. Standard of Care in Emergency Department Sepsis Patients - a Multicenter, Randomized Clinical Feasibility Trial | |||||||||||||
| Medical condition: Sepsis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-004753-68 | Sponsor Protocol Number: HidraQureS/2020 | Start Date*: 2022-09-15 | |||||||||||
| Sponsor Name:Red Andaluza de Diseño y Traslación de Terapias Avanzadas-Fundación Progreso y Salud | |||||||||||||
| Full Title: Phase II, Single-Center, Randomized, Double-blind, Placebo-controlled Clinical Trial to determine the safety and efficacy of the use of allogeneic adipose tissue adult stem mesenchymal cells in the... | |||||||||||||
| Medical condition: Hidradenitis suppurativa | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2007-003210-33 | Sponsor Protocol Number: ERPME01 | Start Date*: 2007-08-03 | |||||||||||
| Sponsor Name:Department of Neurology, Turku University Hospital | |||||||||||||
| Full Title: Effect of ropinirole hydrochloride in progressive myoclonic epilepsy of Unverricht–Lundborg type | |||||||||||||
| Medical condition: Progressive myoclonus epilepsy of the Unverricht–Lundborg disease (ULD) type | |||||||||||||
|
|||||||||||||
| Population Age: | Gender: Male, Female | ||||||||||||
| Trial protocol: FI (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2012-002452-16 | Sponsor Protocol Number: GIDO1201 | Start Date*: 2013-03-15 |
| Sponsor Name:GIDO (Grup d?investigació i divulgació en oncologia) | ||
| Full Title: Estudio Fase II de seguridad de bevacizumab en combinación con carboplatino y paclitaxel en pacientes ancianos (? 70 años) con cáncer de pulmón no microcítico | ||
| Medical condition: Cáncer de pulmón no micricítico avanzado de células no escamosas | ||
| Disease: | ||
| Population Age: Elderly | Gender: Male, Female | |
| Trial protocol: ES (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2013-004396-12 | Sponsor Protocol Number: 02 | Start Date*: 2015-02-03 | |||||||||||
| Sponsor Name:Azienda Ospedaliero-Universitaria Meyer | |||||||||||||
| Full Title: Efficacy of ketamine in refractory convulsive status epilepticus in children: a multicenter, randomized, controlled, open-label, no-profit, with sequential design study. | |||||||||||||
| Medical condition: Refractory convulsive status epilepticus, defined as the recurrence of crisis for more than 60 minutes and / or drug-resistant I l and II line. | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-002426-37 | Sponsor Protocol Number: EA-16-01-077 | Start Date*: 2016-09-27 | |||||||||||
| Sponsor Name:Engelhard Arzneimittel GmbH & Co.KG | |||||||||||||
| Full Title: Randomized, placebo-controlled, double-blind, multi-center trial to evaluate the efficacy and safety of 2 Prospan® posologies (2x 7.5 mL/day and 3x 5 mL/day) in the treatment of acute bronchitis | |||||||||||||
| Medical condition: Acute bronchitis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-000643-27 | Sponsor Protocol Number: VAC071 | Start Date*: 2019-09-23 | |||||||||||
| Sponsor Name:University of Oxford / Clinical Trials and Research Governance | |||||||||||||
| Full Title: A Phase IIa challenge study to assess efficacy of the Plasmodium vivax malaria vaccine candidates ChAd63 PvDBP and MVA PvDBP in healthy adults living in the UK | |||||||||||||
| Medical condition: Plasmodium vivax malaria | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.